Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • Searching Asian documents: patent search and monitoring services
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet and OPS
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Patent insight reports
    • Data
      • Overview
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge

    UP search

    Learn about the Unitary Patent in patent knowledge products and services

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Find a professional representative
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Unitary Patent

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • EPC Guidelines
      • PCT-EPO Guidelines
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National law relating to the UP
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives

    legal text

    Legal texts

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2022 ceremony
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Firefighting technologies
      • Green tech in focus
      • CodeFest on Green Plastics
      • Clean energy technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    Listen to our podcast

  • Learning

    Learning

    The e-Academy – the point of access to your learning

    Go to overview 

    • Overview
    • European Patent Academy
      • Overview
      • Learning activities
      • Learning paths
    • Professional hub
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by area by profile
      • Overview
      • Business and IP managers
      • EQE candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)

    European Patent Academy

    Boost your IP knowledge with (e-)training from the European Patent Academy

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • A glimpse of the planned activities
      • Kids’ collaborative art competition
      • 50 Leading Tech Voices
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Governance
      • Overview
      • Communiqués
      • Calendar
      • Select Committee documents
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Public consultation on the EPO's Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Social responsibility
      • Overview
      • Environment and sustainability
      • Art collection
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s

    about us

    Patent Index 2022

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
  • New to patents
    • Go back
    • Overview
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Your business and patents
    • Is it patentable?
    • Are you first?
    • Why do we have patents?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • Searching Asian documents
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
            • Go back
            • Overview
            • BG - Federated Register Service
            • GB - Federated Register Service
            • NL - Federated Register Service
            • MK - Federated Register Service
            • ES - Federated Register Service
            • GR - Federated Register Service
            • SK - Federated Register Service
            • FR - Federated Register Service
            • MT - Federated Register Service
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Patent insight reports
    • Data
      • Go back
      • Overview
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
          • Go back
          • EBD files (weekly download) - free of charge
            • Go back
            • Secure EBD ST.36 files (weekly download) - for national patent offices only
        • Boards of Appeal decisions
        • EP full-text data for text analytics
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Helpful resources
      • Go back
      • Overview
      • First time here? Patent information explained.
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Unitary Patent Guide
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Online Filing 2.0 pilot
        • MyEPO Portfolio - pilot phase
        • Online Filing 2.0 pilot continuation
        • Exchange data with us using an API
      • Get access
        • Go back
        • Overview
        • Installation and activation
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • EPC Guidelines
        • Go back
        • Overview
        • Archive
      • PCT-EPO Guidelines
        • Go back
        • Overview
        • Archive
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2023 ceremony
      • European Inventor Network
        • Go back
        • Activities granted in 2023
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • CodeFest on Green Plastics
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Patents and standards
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • European Patent Academy
      • Go back
      • Overview
      • Learning activities
      • Learning Paths
    • Professional hub
      • Go back
      • Overview
      • EPAC - European patent administration certification
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Archive
        • Candidates successful in the European qualifying examination
        • Compendium
          • Go back
          • Overview
          • Pre-examination
          • Paper A
          • Paper B
          • Paper C
          • Paper D
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
        • Go back
        • Overview
        • Patent enforcement in Europe
        • Patent litigation in Europe
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventors' handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
            • Go back
            • Overview
            • Is the idea ‘obvious’?
            • Prior art searching
            • Professional patent searching
            • Simple Espacenet searching
            • What is prior art?
            • Why is novelty important?
          • Competition and market potential
            • Go back
            • Overview
            • Research guidelines
          • Assessing the risk ahead
            • Go back
            • Overview
            • Exploitation routes
            • Significant commercial potential
            • Significant novelty
            • What about you?
            • What if your idea is not novel but does have commercial potential?
          • Proving the invention
            • Go back
            • Overview
            • Help with design or redesign
            • Prototype strategy
          • Protecting your idea
            • Go back
            • Overview
            • Forms of IPR
            • Patenting strategy
            • The patenting process
          • Building a team and seeking funding
            • Go back
            • Overview
            • Building a team
            • Sources of funding
            • Sources of help for invention
          • Business planning
            • Go back
            • Overview
            • Constructing a business plan
            • Keep it short!
          • Finding and approaching companies
            • Go back
            • Overview
            • First contact
            • Meetings
          • Dealing with companies
            • Go back
            • Overview
            • Advance or guaranteed payment
            • Companies and your prototype
            • Full agreement – and beyond
            • Negotiating a licensing agreement
            • Reaching agreement
            • Royalties
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • For IP professionals
          • For business decision-makers
          • For stakeholders of the innovation ecosystem
        • IP clinics
      • EQE Candidates
        • Go back
        • Overview
        • Coffee-break questions
        • Daily D questions
        • European qualifying examination - Guide for preparation
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Overview
      • 50 Leading Tech Voices
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Governance
      • Go back
      • Overview
      • Communiqués
        • Go back
        • Overview
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • Invoicing
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • Social responsibility
      • Go back
      • Overview
      • Environment
      • Art collection
        • Go back
        • Overview
        • The collection
        • Let's talk about art
        • Artists
        • Media library
        • What's on
        • Publications
        • Contact
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Procedure
    • Annual reports
      • Go back
      • Overview
    • Organisation
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
        • Composition of the Presidium
          • Go back
          • Overview
          • Archive
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2023
      • Archive
    • Annual list of cases
    • Communications
    • Publications
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
    • Case Law from the Contracting States to the EPC
    • Oral proceedings
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Legal resources
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
      • Specific contact
      • Surveys
        • Go back
        • Overview
        • Search services
        • Examination services, final actions and publication
        • Opposition services
        • Patent filings
          • Go back
          • Overview
          • Detailed methodology
          • Archive
        • Online Services
        • Patent information
          • Go back
          • Overview
          • Innovation process survey
        • Customer services
        • Filing services
        • Website
        • Survey on electronic invoicing
        • Companies innovating in clean and sustainable technologies
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Forums
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2023 decisions
  • 2022 decisions
  • 2021 decisions
https://www.epo.org/en/node/t021127eu1
  1. Home
  2. T 1127/02 (Soluble and insoluble form of an antigen/CONNAUGHT) 14-09-2004
Facebook Twitter Linkedin Email

T 1127/02 (Soluble and insoluble form of an antigen/CONNAUGHT) 14-09-2004

European Case Law Identifier
ECLI:EP:BA:2004:T112702.20040914
Date of decision
14 September 2004
Case number
T 1127/02
Petition for review of
-
Application number
93307185.4
IPC class
A61K 39/00
Language of proceedings
EN
Distribution
DISTRIBUTED TO BOARD CHAIRMEN (C)

Download and more information:

Decision in EN 41.21 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Composition containing both a soluble and an insoluble form of an immunogen

Applicant name
CONNAUGHT LABORATORIES INCORPORATED
Opponent name
GlaxoSmithKline Biologicals s.a.
Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 54 1973
European Patent Convention Art 56 1973
European Patent Convention Art 83 1973
Keywords

Main request - novelty (no)

Auxiliary request - sufficiency of disclosure, novelty, inventive step (yes)

Catchword
-
Cited decisions
T 0256/87
T 0241/89
T 0612/92
T 0694/92
T 0396/99
Citing decisions
T 0478/09
T 1772/09
T 2232/17
T 2886/19

I. The appeal was lodged by the Opponents (Appellants) against the decision of the Opposition Division, whereby the European patent No. 0 588 578 was maintained in amended form pursuant to Article 102(3) EPC.

II. The Opposition Division had decided that claims 1 to 7 of the third auxiliary request before them met the requirements of the EPC.

Claim 1 thereof read:

"A composition for eliciting an immune response to an antigen in an animal, comprising a first physio- chemical form of said antigen favouring presentation of the antigen by B cells to T cells in the animal, and a second physio-chemical form of said antigen favouring presentation of the antigen by accessory cells to T cells in the animal, characterized in that said first physio-chemical form is a soluble form of said antigen and said second physio-chemical form is an insoluble form of said antigen."

III. The Board expressed their preliminary opinion in a communication dated 19 March 2004.

Oral proceedings were held on 14 September 2004.

IV. At the oral proceedings the Patent Proprietors (Respondents) filed an auxiliary request consisting of claims 1 to 4. Claim 1 thereof read:

"A composition for eliciting an immune response to an antigen in an animal, comprising a first physio- chemical form of said antigen favouring presentation of the antigen by B cells to T cells in the animal, and a second physio-chemical form of said antigen favouring presentation of the antigen by accessory cells to T cells in the animal, characterized in that said first physio-chemical form is a soluble form of said antigen and said second physio-chemical form is an insoluble form of said antigen and characterised in that one physio-chemical form of antigen is lipidated and the other physio-chemical form is not lipidated."

V. The Appellants requested that the decision under appeal be set aside and that the patent be revoked.

The Respondents requested that the appeal be dismissed and the patent be maintained on the basis of the main request (claims 1 to 7 as maintained by the Opposition Division), or on the basis of claims 1 to 4 of the auxiliary request filed during oral proceedings.

VI. The following documents are referred to in this decision:

(12) WO-A-91/14 449

(13) Acad. Press Dictionary of Science and Technology; http://www.harcourt.com.dictionary/def/ 9/5/3/9553000.html

(20) J.Immunol., vol. 119, no. 6, 1977, p. 2073 to 2077

(21) Virology, vol. 69, 1976, p. 511 to 522

VII. The submissions by the Appellants as far as they are relevant to the present decision may be summarised as follows:

The two physio-chemical forms of an antigen were defined in claim 1 of the main request, firstly by favouring different paths of presentation of the antigen to T cells, and secondly by the feature that one form was soluble while the other form was insoluble. The first definition was based on a theory to which the Patentees did not wish to be bound. The patent contained no information how to determine the way of presentation of the antigen to T cells. To develop a method for this determination would resume to undue burden. Moreover, the patent lacked any definition of the terms "soluble" and "insoluble" used in the characterising part of claim 1 of the main request. The skilled person working in the field of vaccines would not know when he was working within the area defined by the scope of this claim. Consequently, contrary to the requirements of Article 83 EPC, the patent did not disclose the invention in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art.

The subject matter of claim 1 of the main request was anticipated (Article 54 EPC) at least by the disclosure in documents (12), (20) and (21), which all disclosed a composition containing a soluble and an insoluble form of an antigen.

The claims of the auxiliary request were not acceptable for formal reasons, as they contravened the requirements of Articles 123(2) and 84 EPC. They were open to the same objections under Article 83 EPC as the claims of the main request.

Claim 1 of the auxiliary request lacked novelty over document (12) which disclosed compositions containing a lipidated and a not lipidated form of an antigen.

Starting from either document (12) or (20), no technical problem to be solved could be identified by providing a composition according to claim 1 of the auxiliary request, which for this reason lacked an inventive step.

VIII. The submissions by the Respondents as far as they are relevant to the present decision may be summarised as follows:

The requirements of Article 83 EPC were met by the main request. The patent disclosed three examples of pairs of antigens according to claim 1 of the main request.

Methods for determining the way of presentation of an antigen to T cells were known to the skilled person at the relevant date of the patent in suit. As the soluble form of an antigen was always favourably presented by B cells to T cells, while the insoluble form thereof was favourably presented by accessory cells to T cells, these methods could be used by the skilled person to distinguish between the soluble and insoluble form of an antigen.

Moreover, it was evident from the patent that the solubility/insolubility of an antigen related to the situation after administration of the vaccine, i.e. when the antigen encounters the host's immune system.

None of the documents cited by the Appellants disclosed a composition comprising two physio-chemical forms of an antigen according to claim 1 of the main request.

Document (12) did not disclose a composition comprising a soluble, non-lipidated and an insoluble, lipidated form of an antigen, according to claim 1 of the auxiliary request.

The subject-matter of claim 1 of the auxiliary request was not obvious in the light of document (20), representing the closest prior art, either if taken alone or in combination with any other cited prior art document.

Main Request

Sufficiency of disclosure (Article 83 EPC)

1. In the assessment as to whether a European application fulfils the requirement of Article 83 EPC, it is required according to the case law of the Boards of Appeal that, for the disclosure of an invention to be sufficiently clear and complete, the skilled person, on the basis of the information provided in the application itself and by using the general knowledge, has to be able to achieve the desired result without undue burden and without exercising any inventive skill (cf decisions T 694/92 OJ EPO 1997, 408 and T 612/92 of 28. February 1996).

2. Claim 1 refers to a composition comprising two physio- chemical forms of an antigen. The claim states in its introductory part that the first form of the antigen favours presentation of said antigen by B cells to T cells in an animal, and the second form favours presentation of said antigen by accessory cells to T cells in an animal. This statement reflects a theoretical explanation, given in the patent to explain the technical effect caused by the claimed composition upon administration to a naive animal, namely the achievement of an enhanced immunogenic response (cf page 2, column 2, lines 2 to 54 of the granted patent).

In the specification of the patent it is stated that the Respondents do not wish to be bound to this theory, which, moreover, is not substantiated by any data. In this situation the Board cannot regard this as being a technically characterizing feature of the invention.

3. Consequently, the two physio-chemical forms of an antigen, as defined in the composition of claim 1, are characterized only by the technical feature that one form is "soluble" while the other form is "insoluble".

The Appellants argue that these terms, in the absence of a definition of the solvent used and the temperature applied, do not allow a skilled person to realize if he/she is working within the scope of protection conferred by the claim. By referring to the case law of the Boards of Appeal in decisions T 256/87 of 26 July 1988 and T 241/89 of 14 August 1990, they conclude that the invention is not disclosed sufficiently clear and complete for it to be carried out by a skilled person.

4. The Board does not consider these decisions as being applicable in the present case.

Decision T 256/87 deals with claims to a detergent composition comprising a certain amount of enzyme- accessible calcium (EAC). The competent Board decided that the requirements of Article 84 EPC were met as the description provided a clear and consistent definition of what is meant by EAC. Further, the Board decided that, although no direct analytical method for the determination of EAC was disclosed, the skilled person, by applying indirect empirical investigation, was able to know when he was working within the forbidden area of the claims. This was possible because upper and lower limits claimed were correlated with observable phenomena. Accordingly the requirements of Article 83 EPC were met.

The subject-matter underlying decision T 241/89 was also a detergent composition. It contained not more than 3 mg/kg of reactive titanium (IV). The Board, finding that the disclosure of the patent was insufficient insofar as the method for determining the amount of reactive titanium (IV) was concerned, particularly since this parameter was the only one to distinguish the claimed composition from prior art ones, decided that the requirements of Article 83 EPC were not met.

Thus, in both cases the competent Boards had to decide whether or not the patent contained sufficient disclosure, allowing a skilled person to quantitatively determine the amount of a compound being a technical feature of the claimed composition. This requirement had to be fulfilled in order to put the skilled person in a position where he knows when he is working in the forbidden area of the claims, in accordance with the requirements of Article 83 EPC.

5. The situation underlying the present case is different. Solubility is a characteristic of a substance which depends of the conditions under which it is determined. As for instance mentioned in document (13), the particular solvent used and the temperature applied play an important role.

The patent in suit does not disclose the conditions under which the solubility/insolubility of the two forms of an antigen contained in the claimed composition is determined. Thus, no clear definition of the terms "soluble" and "insoluble" is given, which terms therefore are vague and open to interpretation.

Contrary to the situation as described in the case law of the Boards of Appeal discussed in point (4) above, the skilled person is not in a situation where he is unable to determine the parameter in question, because he is not aware of a single method for doing so. In the present case the Board is convinced that the skilled person, on the basis of his general knowledge, is able to determine if an antigen exists in soluble or in insoluble form under specific conditions given. However, in the absence of a clear definition of the conditions under which the determination is carried out (solvent, temperature) the skilled person is free to choose from a large number of possible conditions when determining solubility/insolubility of the two antigen forms.

6. This may lead to the situation that claim 1 has a very broad scope, but it does not result in lack of sufficiency of disclosure contrary to the requirements of Article 83 EPC, in the sense as established in decision T 241/89 (supra)

7. The absence of a clear definition of the terms "soluble" and "insoluble" used in claim 1, respectively of the conditions under which these characteristics are determined, is considered by the Board to result in a lack of clarity of claim 1.

This cannot be challenged in opposition/appeal proceedings as the requirement that the claims of a European patent shall be clear is laid down in Article 84 EPC, which is not itself a ground for opposition under Article 100(a) EPC. However, questions of clarity or support may affect the decision on issues under Article 100 EPC such as e.g. novelty (Article 54 EPC). If the wording of a claim does not allow a clear distinction of its subject-matter vis-à-vis known subject-matter, Patentee has to be prepared that the claim is interpreted in the broadest possible way.

Novelty (Article 54 EPC)

8. Document (12) discloses a composition for enhancing the immunogenicity of an envelope glycoprotein of a virus, comprising the envelope glycoprotein or a fragment thereof of at least 50 amino acids, and a peptide derived from the envelope glycoprotein which comprises at least one neutralisation epitope (page 2, second paragraph). The word "composition" is intended to comprise a preparation allowing the simultaneous application of the two components (page 2, third paragraph).

The glycoproteins are preferably whole molecules as obtained before possible cleavage (page 12, second full paragraph). The peptides, also designated "amplifiers" can be free or bound to a carrier (page 12, third full paragraph).

9. The Opposition Division stated in the decision under appeal, that document (12) does not contain specific examples showing co-administration of two different forms of an antigen. In view of the fact that document (12) contemplates a number of antigens and combinations of antigens which do not contain a soluble and an insoluble antigen form, they concluded that the general disclosure on page 2 of the less preferred possibility, administering antigens simultaneously or in a mixture, does not anticipate a claim to a composition an accordance with claim 1.

Moreover, they found that in document (12) the term "gp160" is used to designate a glycoprotein obtained from a vaccinia virus VV-1163, coding for the gp160env mutant, which was considered soluble in aqueous solutions as it lacks the transmembrane hydrophobic zone. Consequently, document (12) at the best disclosed compositions comprising two soluble forms of an antigen.

10. The fact that the majority of embodiments disclosed by a prior art document, including the preferred embodiments given in the examples, lie outside the scope of protection of a patent claim under consideration, does not effect that a general disclosure, referring to a less preferred embodiment, which lies within the scope of said claim can be disregarded when examining novelty.

Document (12) explicitly discloses that the preferably used glycoproteins are whole molecules as obtained before possible cleavage (cf page 12). On page 9, first full paragraph it is said that besides gp160env derived from VV-1163, also a version of gp160 containing the hydrophobic transmembrane domain and derived from VV- 1139 is used. It is evident for a skilled person that the presence of a hydrophobic domain prevents the solubility of a protein in aqueous media. Thus, document (12) not exclusively refers to envelope glycoproteins soluble in aqueous solutions.

11. The short amplifier peptides according to document (12) are considered to be soluble in aqueous solutions. This is not disputed by the Respondents.

The Board, considering that no clear definition of the terms "soluble" and "insoluble" is given in claim 1 (see points (3) to (7) above), decides that the disclosure of a composition of an envelope glycoprotein and a peptide derived from its amino acid sequence as disclosed in document (12) anticipates the subject- matter of claim 1 of the main request, which accordingly does not meet the requirement of Article 54 EPC.

Auxiliary Request

Allowability of amendments (Articles 123(2) and 123(3) EPC)

12. Claim 1 corresponds to claim 3 as originally filed and thus meets the requirements of Article 123(2) EPC.

By introducing an additional feature into claim 1 as granted, the protection conferred has been restricted with regard to the claims as granted (Article 123(3) EPC).

Clarity (Article 84 EPC)

13. The Appellants objected that claim 1 lacks clarity as it comprises an embodiment wherein the composition contains a soluble, lipidated form and an insoluble, not lipidated form of an antigen.

14. When considering a claim, one should rule out interpretations which are illogical or which do not make technical sense. One should try to arrive at an interpretation of the claim which is technically sensible and takes into account the whole disclosure of the patent (Article 69 EPC). The claim must be construed by a mind willing to understand not a mind desirous of misunderstanding (cf decision T 396/99, ultimate paragraph of section 3.5).

15. The patent refers to a composition for eliciting an immune response to an antigen in an animal. Lipidated substances are soluble preferably in organic solvents. In the light of the disclosure of the patent as a whole an interpretation of claim 1 as considered possible by the Appellants (cf point (13) above) is technically not sensible.

Sufficiency of disclosure (Article 83 EPC)

16. Compared to claim 1 of the main request, the two forms of an antigen, have been further defined by the technical feature that one form is lipidated and the other form is not lipidated. The patent contains the following examples of such pairs of antigen forms:

- whole inactivated influenza virus and HA(p)

- split HA and HA(p)

- OspA-NL and OspA-L.

The Board is thus convinced that the patent specification puts the skilled person in possession of putting the claimed invention into practice.

Moreover, the Board has no reason to doubt that a skilled person can put the invention into practice over the whole scope of the claim by finding other antigens existing in the two physio-chemical forms required by claim 1. Therefore, the requirements of Article 83 EPC are met.

17. With regard to the use of the terms "soluble" and "insoluble" in claim 1, which are considered to be vague and open to interpretation, the Board refers to points (5) to (7) above.

Novelty (Article 54 EPC)

18. Document (12) discloses compositions comprising an "insoluble" viral envelope glycoprotein and a "soluble" (amplifier-) peptide derived from the amino acid sequence of the envelope glycoprotein (cf points (8) to (11) above).

On page 12, third full paragraph, it is said that the peptides can be associated with other peptides corresponding to T-epitopes, or even to peptides, lipopeptides, or others, capable of stimulating the immune system and/or specifically targeting the "amplifier" peptides to antigen-presenting cells.

The mentioning of lipopeptides in this passage of document (12) refers to subject-matter different from the matter of the claims under consideration. A composition comprising an envelope glycoprotein and an amplifier-peptide associated with a lipopeptide, as defined on page 12 of document (12), does not anticipate the novelty of claim 1 of the auxiliary request.

19. Document (20) discloses the potentiation of poorly immunogenic subunit influenza virus vaccines by a small dose of whole virus vaccine. Hemagglutinin (HA) and neuraminidase (NA) subunit vaccine is prepared from virus particles by disruption with ammonium deoxycholate and administered to unprimed animals and humans together with varying amounts of heterologous and homologous whole virus particles.

It was shown in tables II, III and V that the antibody response to the subunit vaccine could be potentiated by a small dose of whole virus, both in hamsters and seronegative young adults.

Document (21), from the same authors, contains essentially the same teaching.

This state of the art does not disclose a composition according to claim 1, containing two physio-chemical forms of an antigen, characterized in that one is lipidated and the other is not lipidated.

20. The Board decides that the subject-matter of claim 1, and of claims 2 to 4 dependent thereon, is novel and meets the requirements of Article 54 EPC.

Inventive step (Article 56 EPC)

21. In accordance with the problem and solution approach, the Boards of Appeal in their case law have developed certain criteria for identifying the closest prior art providing the best starting point for assessing inventive step. It has been repeatedly pointed out that this should be a prior art document disclosing subject-matter conceived for the same purpose or aiming at the same objective as the claimed invention and having the most relevant technical features in common , i.e. requiring the minimum of structural modifications (cf Case Law of the Boards of Appeal of the European Patent Office, 4th Edition 2001, chapter I.D.3.1).

22. While the Appellants consider both, documents (12) and (20) as being suitable starting points for the application of the problem and solution approach, the Board is of the opinion that document (20), disclosing a composition comprising whole virus particles and a subunit vaccine as representing the closest prior art, as it has the same aim as the patent in suit, namely to enhance the immune response of weakly immunogenic materials in naive animals (see patent in suit, page 2, column 1, lines 10 to 12 and lines 44 to 48 and document (20), abstract).

23. In the light of the disclosure in document (20) the technical problem to be solved by the patent in suit is seen as the provision of an alternative vaccine composition.

24. This problem is solved by the composition according to claim 1, comprising two physio-chemical forms of an antigen, wherein the first form is a soluble form and the second form is an insoluble form, and wherein one form is lipidated and the other form is not lipidated.

The remarkably improved effect obtained by co- administration of HA(p) and whole inactivated virus can be seen in Figure 1 of the patent in suit (cf groups 7 and 8).

25. Documents (20) and (21), as well the other prior art documents on file, do neither disclose nor hint at the provision of an antigen in a lipidated and a not lipidated from. Thus, the skilled person does not get any information that would encourage him to further develop the disclosure in the closest prior art and to arrive at the subject-matter of claim 1 in an obvious way.

Claims 1 to 4 of the auxiliary request are based on an inventive step and meet the requirements of Article 56 EPC.

Order

ORDER

For these reasons it is decided:

1. The decision under appeal is set aside.

2. The case is remitted to the first instance with the order to maintain the patent on the basis of the following documents:

claims: 1 to 4 filed during oral proceedings on 14 September 2004 as auxiliary request

description: pages 2 and 3 filed during the oral proceedings, pages 4 and 5 as granted

Figures: 1 to 9 as granted

Footer - Service & support
  • Service & support
    • FAQ
    • Contact us
    • Subscription centre
    • Official holidays
    • Publications
    • Procedural communications
    • Ordering
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
SoMe facebook 0
European Patent Office
EPO Jobs
SoMe instagram
EuropeanPatentOffice
SoMe linkedIn
European Patent Office
EPO Jobs
EPO Procurement
SoMe twitter
EPOorg
EPOjobs
SoMe youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility